QUÉBEC CITY, May 22, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS, TSX: AEZ) (the "Company") today announced that a poster will be
presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic
endometrial cancer. The poster will be presented by lead investigator,
David S. Miller MD, of the University of Texas Southwestern Medical
Center in Dallas, during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), to
be held May 30-June 4, 2014 in Chicago. There are currently over 100
sites in operation and over 150 patients have been recruited for this
ZoptEC Phase 3 trial.
"ZoptEC: Phase 3 study of zoptarelin doxorubicin (AEZS-108) in
platinum-taxane pretreated endometrial cancer (Study AEZS-108-050)", David S. Miller, Hani Gabra, Guenter Emons, D. Scott McMeekin, Amit
M. Oza, Sarah Madhu Temkin, Ignace Vergote.
Dr. David S. Miller
|Poster Session: ||
|Date & Time: ||
Saturday, May 31, 2014, 8:00 am - 11:45 am (Central time)
SHall A2, McCormick Place, Chicago
About Zoptarelin Doxorubicin
Zoptarelin doxorubicin represents a new targeting concept in oncology
using a hybrid molecule composed of a synthetic peptide carrier and a
well-known chemotherapy agent, doxorubicin. Zoptarelin doxorubicin is
the first intravenous drug in advanced clinical development that
directs the chemotherapy agent specifically to LHRH-receptor expressing
tumors, resulting in a more targeted treatment with less damage to
healthy tissue. The Company is currently conducting a Phase 3 trial in
endometrial cancer under a Special Protocol Assessment, while
zoptarelin doxorubicin is also in an investigator-initiated Phase 2
trial in prostate cancer. Aeterna Zentaris owns the worldwide rights to
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in
developing novel treatments in oncology and endocrinology. The
Company's pipeline encompasses compounds at various stages of
development. For more information, visit www.aezsinc.com.
SOURCE Aeterna Zentaris Inc.